These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 8708718)
1. Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. Seymour MT; Slevin ML; Kerr DJ; Cunningham D; James RD; Ledermann JA; Perren TJ; McAdam WA; Harper PG; Neoptolemos JP; Nicholson M; Duffy AM; Stephens RJ; Stenning SP; Taylor I J Clin Oncol; 1996 Aug; 14(8):2280-8. PubMed ID: 8708718 [TBL] [Abstract][Full Text] [Related]
2. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group. J Clin Oncol; 1995 Apr; 13(4):921-8. PubMed ID: 7707120 [TBL] [Abstract][Full Text] [Related]
3. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. Köhne CH; Schöffski P; Wilke H; Käufer C; Andreesen R; Ohl U; Klaasen U; Westerhausen M; Hiddemann W; Schott G; Harstick A; Bade J; Horster A; Schubert U; Hecker H; Dörken B; Schmoll HJ J Clin Oncol; 1998 Feb; 16(2):418-26. PubMed ID: 9469324 [TBL] [Abstract][Full Text] [Related]
4. Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study. Seymour MT; Johnson PW; Hall MR; Wrigley PF; Slevin ML Br J Cancer; 1994 Oct; 70(4):719-23. PubMed ID: 7917927 [TBL] [Abstract][Full Text] [Related]
5. Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study. Punt CJ; Burghouts JT; Croles JJ; van Liessum PA; de Mulder PH; Kamm Y Cancer; 1993 Oct; 72(7):2107-11. PubMed ID: 8374869 [TBL] [Abstract][Full Text] [Related]
6. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. Jäger E; Heike M; Bernhard H; Klein O; Bernhard G; Lautz D; Michaelis J; Meyer zum Büschenfelde KH; Knuth A J Clin Oncol; 1996 Aug; 14(8):2274-9. PubMed ID: 8708717 [TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). Köhne CH; Wilke H; Hecker H; Schöffski P; Käufer C; Rauschecker H; Andreesen R; Ohl U; Lange HJ; Klaassen U Ann Oncol; 1995 May; 6(5):461-6. PubMed ID: 7669711 [TBL] [Abstract][Full Text] [Related]
8. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). Tournigand C; Louvet C; de Gramont A; Lucchi E; Seitz JF; Mal F; Raymond E; Cady J; Carola E; Krulik M Cancer; 1997 Mar; 79(6):1094-9. PubMed ID: 9070485 [TBL] [Abstract][Full Text] [Related]
9. 5-Fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration. Buter J; Sinnige HA; Sleijfer DT; de Vries EG; Willemse PH; van der Graaf WT; Verschueren RC; Mulder NH Cancer; 1995 Mar; 75(5):1072-6. PubMed ID: 7850703 [TBL] [Abstract][Full Text] [Related]
10. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. O'Dwyer PJ; Manola J; Valone FH; Ryan LM; Hines JD; Wadler S; Haller DG; Arbuck SG; Weiner LM; Mayer RJ; Benson AB J Clin Oncol; 2001 May; 19(9):2413-21. PubMed ID: 11331320 [TBL] [Abstract][Full Text] [Related]
11. Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. Greco FA; Figlin R; York M; Einhorn L; Schilsky R; Marshall EM; Buys SS; Froimtchuk MJ; Schuller J; Schuchter L; Buyse M; Ritter L; Man A; Yap AK J Clin Oncol; 1996 Oct; 14(10):2674-81. PubMed ID: 8874326 [TBL] [Abstract][Full Text] [Related]
12. A clinical and pharmacological study of 5-fluorouracil, leucovorin and interferon alfa in advanced colorectal cancer. Moore MJ; Kaizer L; Erlichman C; Myers R; Feld R; Thiessen JJ; Fine S Cancer Chemother Pharmacol; 1995; 37(1-2):86-90. PubMed ID: 7497602 [TBL] [Abstract][Full Text] [Related]
13. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. Köhne CH; Wils J; Lorenz M; Schöffski P; Voigtmann R; Bokemeyer C; Lutz M; Kleeberg C; Ridwelski K; Souchon R; El-Serafi M; Weiss U; Burkhard O; Rückle H; Lichnitser M; Langenbuch T; Scheithauer W; Baron B; Couvreur ML; Schmoll HJ; J Clin Oncol; 2003 Oct; 21(20):3721-8. PubMed ID: 12963704 [TBL] [Abstract][Full Text] [Related]
14. Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study. Hausmaninger H; Moser R; Samonigg H; Mlineritsch B; Schmidt H; Pecherstorfer M; Fridrik M; Kopf C; Nitsche D; Kaider A; Ludwig H Eur J Cancer; 1999 Mar; 35(3):380-5. PubMed ID: 10448286 [TBL] [Abstract][Full Text] [Related]
15. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076 [TBL] [Abstract][Full Text] [Related]
16. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. Hill M; Norman A; Cunningham D; Findlay M; Watson M; Nicolson V; Webb A; Middleton G; Ahmed F; Hickish T J Clin Oncol; 1995 Sep; 13(9):2317-23. PubMed ID: 7666089 [TBL] [Abstract][Full Text] [Related]
17. Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin. Schwartzberg LS; Petak I; Stewart C; Turner PK; Ashley J; Tillman DM; Douglas L; Tan M; Billups C; Mihalik R; Weir A; Tauer K; Shope S; Houghton JA Clin Cancer Res; 2002 Aug; 8(8):2488-98. PubMed ID: 12171874 [TBL] [Abstract][Full Text] [Related]
18. Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administration. Steger GG; Mader RM; Djavanmard MP; Gnant MF; Locker G; Marosi C; Rainer H; Jakesz R J Cancer Res Clin Oncol; 1994; 120(5):314-8. PubMed ID: 8126062 [TBL] [Abstract][Full Text] [Related]
19. Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma. Grem JL; Jordan E; Robson ME; Binder RA; Hamilton JM; Steinberg SM; Arbuck SG; Beveridge RA; Kales AN; Miller JA J Clin Oncol; 1993 Sep; 11(9):1737-45. PubMed ID: 8355041 [TBL] [Abstract][Full Text] [Related]
20. A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma. Shapiro JD; Harold N; Takimoto C; Hamilton JM; Vaughn D; Chen A; Steinberg SM; Liewehr D; Allegra C; Monahan B; Lash A; Grollman F; Flemming D; Behan K; Johnston PG; Haller D; Quinn M; Morrison G; Grem JL Clin Cancer Res; 1999 Sep; 5(9):2399-408. PubMed ID: 10499610 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]